Featured Posts
Recent Posts
Please reload

Peter Speaks with Jo Eames at the Action Duchenne Conference

January 16, 2018

Please reload

Resolaris Granted Orphan Drug Designation for LGMD & FSHMD

March 17, 2017

The European Medicines Agency has granted Orphan Drug Designation to Resolaris (ATYR1940) for the treatment of all types of limb girdle muscular dystrophy (LGMD) & Facioscapulohumeral MD (FSHMD).

In muscular dystrophies like LGMD, inflammation contributes to muscle damage. The aim of the protein Resolaris is to reduce inflammation by altering the body’s immune response.

aTyr Pharma recently reported its phase Ib/II trial for Resolaris, testing it in patients with LGMD 2B, which found it to be safe and did not suppress circulating immune cells. It also displayed effectiveness, improving muscle function in 7 of the 9 treated patients after 14 weeks.

While the overall muscle strength improvement in the trial was reasonably small (6% compared to baseline/scores recorded prior to the treatment), the trial has now been extended to monitor the drug’s effect longer term.



Please reload

Please reload

Search By Tags